Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Paxil CR In Recovery, But Still Hobbling GSK’s U.S. Rx Sales Growth

This article was originally published in The Pink Sheet Daily

Executive Summary

Controlled-release paroxetine recaptures 41% of pre-seizure new prescription share, but the sales interruption still slows growth of GSK’s U.S. pharma business during the second quarter.

You may also be interested in...



Forest To Use New Data To Promote Lexapro In Face Of Paxil CR Relaunch

Lexapro market share gain is behind expectations because of the market reentry of GlaxoSmithKline’s Paxil CR, increased detailing by antidepressant competitors and more aggressive promotion of generics by payors.

Forest To Use New Data To Promote Lexapro In Face Of Paxil CR Relaunch

Lexapro market share gain is behind expectations because of the market reentry of GlaxoSmithKline’s Paxil CR, increased detailing by antidepressant competitors and more aggressive promotion of generics by payors.

Takeda’s Actoplus Met For Type 2 Diabetes Will Launch In October

FDA approves the single-pill combination of Takeda’s Actos (pioglitazone) and metformin.

Related Content

Topics

UsernamePublicRestriction

Register

PS062648

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel